HealthEquity (NASDAQ:HQY) Cut to Hold at Wall Street Zen

Wall Street Zen downgraded shares of HealthEquity (NASDAQ:HQY) from a buy rating to a hold rating in a report published on Saturday,Wall Street Zen reports.

Other research analysts have also recently issued reports about the stock. Barrington Research reissued an “outperform” rating and issued a $110.00 price objective on shares of HealthEquity in a research note on Friday, May 22nd. Citigroup restated a “market outperform” rating on shares of HealthEquity in a research note on Friday, August 28th. Weiss Ratings reissued a “hold (c+)” rating on shares of HealthEquity in a report on Wednesday, September 2nd. Raymond James Financial reiterated a “strong-buy” rating on shares of HealthEquity in a research report on Thursday. Finally, Telsey Advisory Group set a $111.00 target price on HealthEquity in a research note on Friday, August 28th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $111.87.

HealthEquity Price Performance

HQY stock opened at $96.07 on Friday. HealthEquity has a 52 week low of $72.76 and a 52 week high of $107.62. The business has a 50-day simple moving average of $99.53 and a 200 day simple moving average of $88.86. The company has a quick ratio of 2.99, a current ratio of 2.99 and a debt-to-equity ratio of 0.47. The company has a market cap of $7.95 billion, a PE ratio of 34.68, a price-to-earnings-growth ratio of 1.52 and a beta of 0.22.

HealthEquity (NASDAQ:HQY) last announced its quarterly earnings data on Thursday, August 27th. The company reported $1.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.19 by $0.05. HealthEquity had a net margin of 17.36% and a return on equity of 15.33%. The firm had revenue of $350.73 million for the quarter, compared to the consensus estimate of $349.22 million. The firm’s revenue was up 95.5% compared to the same quarter last year. HealthEquity has set its FY 2027 guidance at 4.660-4.730 EPS. Sell-side analysts anticipate that HealthEquity will post 3.93 EPS for the current fiscal year.

Insider Buying and Selling at HealthEquity

In other news, EVP Michael Fiore sold 2,470 shares of the stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $95.00, for a total value of $234,650.00. Following the completion of the transaction, the executive vice president directly owned 56,643 shares in the company, valued at approximately $5,381,085. This represents a 4.18% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Adrian Dillon sold 7,632 shares of the business’s stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $104.61, for a total value of $798,383.52. Following the sale, the director owned 62,395 shares in the company, valued at $6,527,140.95. This represents a 10.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 12,456 shares of company stock valued at $1,256,664 over the last quarter. Company insiders own 1.60% of the company’s stock.

Institutional Trading of HealthEquity

Hedge funds and other institutional investors have recently made changes to their positions in the company. Oxbow Advisors LLC bought a new position in shares of HealthEquity during the first quarter valued at $3,147,000. Deutsche Bank AG bought a new stake in shares of HealthEquity in the second quarter worth $11,986,000. Maridea Wealth Management LLC bought a new stake in shares of HealthEquity in the second quarter worth $2,753,000. Westfield Capital Management Co. LP increased its holdings in HealthEquity by 13.7% in the fourth quarter. Westfield Capital Management Co. LP now owns 1,952,452 shares of the company’s stock valued at $178,864,000 after purchasing an additional 235,794 shares during the period. Finally, Future Fund LLC increased its holdings in HealthEquity by 40.9% in the fourth quarter. Future Fund LLC now owns 44,317 shares of the company’s stock valued at $4,060,000 after purchasing an additional 12,854 shares during the period. 99.55% of the stock is currently owned by institutional investors.

About HealthEquity

HealthEquity, Inc (NASDAQ: HQY) is a leading administrator of consumer-directed health accounts and related benefit solutions in the United States. Founded in 2002 and headquartered in Draper, Utah, the company specializes in health savings accounts (HSAs) and offers complementary services such as flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), COBRA administration and commuter benefits. Through its technology-driven platform, HealthEquity enables employers, health plans and individuals to streamline account management, improve cost transparency and encourage more informed healthcare spending.

Serving millions of members across all 50 states, HealthEquity leverages an open-architecture ecosystem that integrates with health plans, payroll providers and financial institutions.